10:01 , Sep 28, 2018 |  BC Extra  |  Financial News

Flagship leads $80M round for immunotherapy play KSQ

KSQ Therapeutics Inc. (Cambridge, Mass.) plans to use the proceeds from an $80 million series C round to advance its first program -- a modified adoptive T cell immunotherapy -- into the clinic within the...
22:13 , Oct 6, 2017 |  BioCentury  |  Finance

CRISPRing out new targets

Flagship Pioneering believes the CRISPRomics drug discovery technology of recently unveiled KSQ Therapeutics Inc. may have the potential to greatly reduce false positives in drug discovery. On Oct. 2, KSQ emerged from stealth mode with...
18:10 , Oct 6, 2017 |  BC Week In Review  |  Financial News

KSQ debuts with $76M financing

On Oct. 2, CRISPR-associated protein 9 (Cas9)-based therapeutic company KSQ Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with a $76 million financing led by Flagship Pioneering, with participation from Polaris Partners, Arch Venture Partners and...
11:05 , Oct 2, 2017 |  BC Extra  |  Financial News

KSQ debuts with $76M funding

CRISPR-associated protein 9 (Cas9)-based therapeutic company KSQ Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with a $76 million financing led by Flagship Pioneering, with participation from Polaris Partners, Arch Venture Partners and Alexandria Equities. The...
07:00 , Sep 14, 2015 |  BioCentury  |  Finance

Periodic piece

About a decade after an Arch Venture-led syndicate formed Ikaria Inc. to develop elemental reducing agents for critical care, the firm is going back for round two with the technology. Although the assets have been...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Financial News

Calimmune completes venture financing

Calimmune Inc. , Tucson, Ariz.   Business: Infectious   Date completed: 2015-05-27   Type: Venture financing   Raised: $15 million   Investors: Alexandria Equities; RA Capital Healthcare Fund L.P.; Translational Accelerator LLC; undisclosed pharmaceutical company...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Flex Pharma completes venture financing

Flex Pharma Inc. , Boston, Mass.   Business: Neurology   Date completed: 2014-09-08   Type: Venture financing   Raised: $40 million   Investors: Longwood Fund; Bessemer Venture Partners; EcoR1 Capital; Jennison Associates; Lightstone Ventures; Alexandria...
02:14 , Sep 9, 2014 |  BC Extra  |  Financial News

Newco Flex raises $40 million in venture round

Flex Pharma Inc. (Boston, Mass.) raised $40 million in an undisclosed venture round to develop treatments for neuromuscular disorders. Investors include Longwood Fund; Bessemer Venture Partners; EcoR1 Capital; Jennison Associates; Lightstone Ventures; Alexandria Equities; CD-Venture;...
07:00 , Sep 8, 2014 |  BioCentury  |  Emerging Company Profile

Flex: Flexing muscle

Flex Pharma Inc. is developing an ion channel activator that could be the first therapeutic approved to treat nighttime leg cramps, and muscle cramps and spasticity associated with diseases like multiple sclerosis and spinal spasticity....
07:00 , Apr 16, 2007 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Spaltudaq Corp. Seattle, Wash. Technology: Human B cell-based monoclonal antibody discovery platform Disease focus: Cancer, infectious Clinical status: Late research/early preclinical Founded: 2004 by Johnny Stine University collaborators: ND Corporate partners: None Number of employees:...